 Oral composition |
| OF THE INVENTION Although the present invention is described below with reference to examples, the ... |
|
| Formulation for administration of steroid compounds |
| OF THE INVENTION By 5.beta. steroid is meant .alpha. ET, .beta. ET, and ED. In addition certain ... |
|
| Geldanamycin derivatives and antitumor drug |
| OF THE PREFERRED EMBODIMENTS The Geldanamycin derivatives having the formula (I) can be produced ... |
|
| Method and compositions for inhibiting protein kinases |
| We claim: 1. A method for inhibiting a protein kinase, which comprises: contacting a composition ... |
|
| Identification of drug candidates modulating factor VII-mediated intracellular signaling |
| OF THE INVENTION The present invention relates to the use of FVII or FVIIa or another TF agonist ... |
|
| Method for providing enteric coating on solid dosage forms and aqueous compositions therefor |
| OF THE PREFERRED EMBODIMENTS Extensive investigations have been undertaken by the inventors with ... |
|
|
Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient
| Details |
Inventors: Tanouchi, Tadao; Kawamura, Masanori; Ajima, Akio; Mohri, Tetsuya; Hayashi, Masaki; Terashima, Hiroshi; Hirata, Fumio; Morimura, Takeshi;
Assignee: Ono Pharmaceutical Co., Ltd. (Osaka, JP)
Primary Examiner: Gerstl; Robert
Assistant Examiner:
Attorney, Agent or Firm: Sughrue, Mion, Zinn, Macpeak, and Seas
The rhodanine derivatives of the general formula: ##STR1## [wherein (I) R.sup.1 and R.sup.2 are taken together to represent a tetramethylene or pentamethylene group; (II) R.sup.1 represents a hydrogen atom, and R.sup.2 represents (1) a cycloalkyl or cycloalkenyl group of 4-7 carbon atoms which is unsubstituted or substituted by at least one alkyl group of 1-4 carbon atoms, (2) an anthryl or naphthyl group, (3) a phenyl group which is unsubstituted or substituted by at least one of (a) halogen atom, (b) trifluoromethyl group, (c) hydroxyl group, (d) nitro group, (e) carboxyl group, (f) amino group which may be substituted by alkyl group(s) of 1-4 carbon atoms, (g) alkyl, alkoxy or alkylthio group of 1-5 carbon atoms, (h) phenyl group, (i) heterocyclic group containing at least one of nitrogen, oxygen and sulfur atoms which is unsubstituted or substituted by at least one of the above-described substituents (a) to (h), and (j) alkyl group of 1-4 carbon atoms which is substituted by at least one of the above-described substituents (c), (h) and (i), (4) a heterocyclic group containing at least one of nitrogen, oxygen and sulfur atoms which is unsubstituted or substituted by at least one of oxo group and the above-described substituents (a) to (h) and (j), or (5) a ##STR2## (wherein R.sup.4 represents a hydrogen atom, a halogen atom, phenyl group or an alkyl group of 1-5 carbon atoms; and R.sup.5 represents a hydrogen atom, a phenyl group or an alkyl group of 1-5 carbon atoms) or ##STR3## or (III) R.sup.1 and R.sup.2, which may be the same or different with each other, each represents a phenyl group which is unsubstituted or substituted by at least one of the above-described substituents (a) to (j); and R.sup.3 represents a hydrogen atom, an alkyl group of 1-12 carbon atoms, an aralkyl group of 7-13 carbon atoms, a cycloalkyl or cycloalkenyl group of 4-7 carbon atoms which is unsubstituted or substituted by at least one alkyl group of 1-4 carbon atoms, or a phenyl group which is unsubstituted or substituted by at least one of the above-described substituents (a) to (j)] and, when R.sup.3 represents a hydrogen atom, non-toxic salts of the acids possess a strong inhibitory activity on aldose reductase, and are useful for the prevention and treatment of nerve disturbances such as neuralgia, retinopathy, diabetic cataract and renal disturbances such as tubular nephropathy. |
|
DETAILED DESCRIPTION I claim: 1.
A rhodanine derivative represented by the general formula: ##STR13## wherein R.
sup.
11 represents a hydrogen atom; R.
sup.
22 represents: (1) a 5- to 10-membered mono or bicyclic heterocyclic group containing one of nitrogen, oxygen and sulfur atoms which is substituted by at least one member selected from the group consisting of (b) trifluoromethyl group, (e) carboxyl group, (f) amino group which may be substituted by alkyl group(s) of 1-4 carbon atoms, (g-3) alkoxy group of 1-5 carbon atoms, and (j) alkyl group of 1-4 carbon atoms which is substituted by at least one of: (c) hydroxyl group, and (i) 5- to 10-membered mono or bicyclic heterocyclic group containing one or two nitrogen, oxygen and sulfur atoms which is unsubstituted or substituted by at least one member selected from the group consisting of (a) halogen atom, (d) nitro group, (g) alkyl, alkoxy or alkylthio group of 1-5 carbon atoms and one member selected from the group consisting of the above-described substituents (b), (c), (e), (f) and (h), or (2) ##STR14## R.
sup.
3 represents a hydrogen atom, an alkyl group of 1-12 carbon atoms, an aralkyl group of 7-13 carbon atoms, a cycloalkyl or cycloalkenyl group of 7-13 carbon atoms, a cycloalkyl or cycloalkenyl group of 4-7 carbon atoms which is unsubstituted or substituted by at least one alkyl group of 1-4 carbon atoms, or a phenyl group which is unsubstituted or substituted by at least one member selected from the group consisting of the above-described substituents (a), (b), (c), (d), (e), (f), (g), (h), (i) and (j) or, when R.
sup.
3 represents a hydrogen atom, non-toxic salts of the acids.
2.
A rhodanine derivative as described in claim 1, wherein R.
sup.
3 is a hydrogen atom or an alkyl group of 1-12 carbon atoms, or when R.
sup.
3 represents a hydrogen atom, a non-toxic salt of the acid.
3.
A rhodanine derivative as described in claim 1, wherein R.
sup.
11 represents a hydrogen atom and R.
sup.
22 is a 2-thienyl, 5-hydroxymethyl-2-furyl, 2-pyrrolyl, 5-methoxy-3-indolyl, 2-isopropyl-5-methoxy-3-indolyl, 5-nitro-3-indolyl, 5-carboxy-3-indolyl, 1-methyl-3-indolyl, 2-methyl-3-indolyl, 2-isopropyl-3-indolyl, 3-benzo[b]furyl, 3-benzo[b]thienyl, 5-(3-pyridylmethyl)-2-thienyl, 1-butyl-3-indolyl, 1-benzyl-3-indolyl or 2-isopropyl-5-nitro-3-indolyl group or a non-toxic salt of the acid when R
|
| Related patents |
|
|
Fuel supply systems
We claim: 1. A liquid fuel pump arrangement for delivering liquid fuel to an engine comprising a liquid-ring pump including a motor-driven bladed impeller rotor which is ...
|
|
|
Heterocyclic oxophthalazinyl acetic acids
OF THE INVENTION The numbering system of the compounds of formula I is as shown: ##STR5## The term "(C.sub.1 -C.sub.4)alkyl" whenever used in the definitions of R.sub.1 ...
|
|
|
Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors
We claim: 1. The compounds of structural formula (I) ##STR5## wherein R.sup.1 and R.sup.2 are independently hydrogen, alkyl containining 1 to 6 carbon atoms, halogen, ...
|
|
|
Novel alpha-glucosidase inhibitor, pradimicin Q
OF THE INVENTION One aspect of the present invention provides the compound pradimicin Q and its pharmaceutically acceptable base salts. "Pharmaceutically acceptable ...
|
|
|
.alpha.-glucosidase inhibitors
What is claimed is: 1. 1-deoxy nojirimycin derivatives of the formula ##STR5## and the pharmaceutically acceptable acid addition salts thereof wherein n is zero, 1 or 2 ...
|
|
|
Oxetanones
OF THE INVENTION As used herein, the term "alkyl" denotes a straight or branched chain alkyl containing the number of carbon atoms designated. Examples of C.sub.1 -C....
|
|
|
Process for the preparation of .alpha.-glucosidase inhibitor, pradimicin Q
OF THE INVENTION One aspect of the present invention provides the compound pradimicin Q and its pharmaceutically acceptable base salts. "Pharmaceutically acceptable ...
|
|
|
Pyridopyrimidine derivatives, pharmaceutical compositions containing them and process for preparing same
We claim: 1. A compound of the Formula (I) ##STR7## wherein R is a C.sub.1 to C.sub.12 alkyl group substituted by C.sub.1 to C.sub.4 alkoxycarbonyl, a C.sub.3 to C.sub.9 ...
|
|
|
Inhibitor of absorption of digestion product of food and drink
OF THE INVENTION The following examples are to explain this invention in detail, not to limit its scope. EXAMPLE 1 Acqueous Enteric Material--Flocculant (a) Granules of ...
|
|
|
Hydantoin derivatives for treating complications of diabetes
OF PREFERRED EMBODIMENTS The invention will now be further explained with reference to Manufacturing Examples of the compounds and salts, Pharmacological Test Examples ...
|
|
|
Weight Loss and Supplements 
